Home » News » AFR Article on how CSL priced the world’s most expensive drug

AFR Article on how CSL priced the world’s most expensive drug

December 8th, 2022

CSL is one of Australia’s greatest business and technical success stories and its shares have provided one of the best returns on the ASX among listed companies over the past decade.

CSL has also been a very strong advocate of the R&D Tax Incentive and lobbied for maintenance of a strong and stable incentive to encourage local investment in R&D.

A recent article in the Australian Financial review has detailed the process around receipt of US regulatory approval for the most expensive drug in the world – CSL’s world’s first gene therapy for haemophilia B is priced at $US3.5 million ($5 million) per dose.

The company’s head of R&D Bill Mezzanotte told The Australian Financial Review that there are many factors that go into pricing a drug, including development costs. “The current estimate is that for every successful product you bring to market, you spend an average of $US1 billion to $US2 billion in R&D,” he said. CSL’s compound, Hemgenix, has been developed over 10 years, but the science of delivering gene therapy is more than 20 years old, and that needs to be taken into account.

For Hemgenix, the other major factor noted was healthcare savings. Haemophilia B is a rare, chronic bleeding disorder caused by a gene defect, with the current treatment being prophylactic infusions of a protein called factor IX, which people with the condition do not produce enough of naturally. Infusions are twice weekly or fortnightly, for the rest of a patient’s life.

“You can’t even measure the difference in a person’s life taking one treatment and not need to think about it for at least 10 to 20 years,” Dr Mezzanotte said. “It’s not just their convenience, it’s their sense of mental security, and of course, it saves the healthcare system a lot of money in both the cost of therapy, rescue therapies, the cost of treating a bleed and also the lost productivity of these patients.” Studies have found haemophilia B patients cost the healthcare system more than $US20 million over their lifetime, and that at $US2.5 million a dose, the health system would save more than $US7 million per patient.

Since the announcement, CSL’s share price has had no dramatic changes, with the market anticipating this approval after the company’s positive phase three trial data in February. However, analysts were expecting Hemgenix to cost around $US2 million, so with the $US3.5 million price it is expected the company’s market value will increase in the 2024-25 financial year.

CSL said they didn’t expect changes over night. At the company’s R&D day earlier this month, chief commercial officer Bill Campbell said, “we think gene therapy is a really important innovation … it’s been the hope and dream of haemophilia B patients for at least 25 years … but it will take a little bit of time for questions to be answered in the commercial space”.

Are You Eligible?

Click here for the R&D Eligibility Wizard

R&D Audit Checklist

Archives

         Posted on Google  
   
   Daniel McGregor  
 11. August, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  I have been using Swanson Reed for my clients for more than a decade.  Having a specialist firm that can provide practical and commercial advice that produces real outcomes is very important and we have received great feedback from our clients. Highly recommended.
  
 
 
      Posted on Google  
   
   John  
 15. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian and the rest of the team at Swanson Reed have been supporting us for several years.  We always appreciate their insights, expertise, and efforts.
  
 
 
      Posted on Google  
   
   Rueben Rajasingam  
 6. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Experienced responsive Team. They have been a great help to me and my company navigate the R&D tax claim process and have provided invaluable advice.
  
 
 
      Posted on Google  
   
   Enrique Esquivel  
 6. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian and the team at Swanson Reed have been extremely helpfully and professional during all of our consultations. Highly recommended.
  
 
 
      Posted on Google  
   
   Jess at Y&C  
 3. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  
  
 
 
      Posted on Google  
   
   Anatole Kononewsky  
 2. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  The Swanson Reed team have provided our company with exceptional professional advice and assistance for all of our R&D claims for many years - have always achieved great results with excellent value for their services.
  
 
 
      Posted on Google  
   
   Payam Toloo  
 2. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian Smyth and his team are very helpful, supportive and experts in their field of R&D Tax claims. I'm always happy with the work they do and been a customer of their for over 5 years.
  
 
 
      Posted on Google  
   
   Melissa Doddy  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  The Team at Swanson Reed are very experienced R&D Tax Advisors and gave us ongoing support with all of our R&D Claims, the consultants ensured we were always working with current legislative guidelines, gave us assistance with compiling technical and government documentation and went out their way to ensure they were with us for the entire process from beginning to end.  Highly recommended to anyone who needs assistance with working through what can at times be a daunting process.
  
 
 
      Posted on Google  
   
   Gary Watson  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  We can highly recommend Swanson and Reed as an R & D accountant. We have worked with them for several years now as they make our R & D claim so easy and communicate quickly with both us and our accountant.
  
 
 
      Posted on Google  
   
   Rob van den Bergh  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Always professional.
  
 
 
  
  Load more

         Posted on Google  
   
   Daniel McGregor  
 11. August, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  I have been using Swanson Reed for my clients for more than a decade.  Having a specialist firm that can provide practical and commercial advice that produces real outcomes is very important and we have received great feedback from our clients. Highly recommended.
  
 
 
      Posted on Google  
   
   John  
 15. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian and the rest of the team at Swanson Reed have been supporting us for several years.  We always appreciate their insights, expertise, and efforts.
  
 
 
      Posted on Google  
   
   Rueben Rajasingam  
 6. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Experienced responsive Team. They have been a great help to me and my company navigate the R&D tax claim process and have provided invaluable advice.
  
 
 
      Posted on Google  
   
   Enrique Esquivel  
 6. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian and the team at Swanson Reed have been extremely helpfully and professional during all of our consultations. Highly recommended.
  
 
 
      Posted on Google  
   
   Jess at Y&C  
 3. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  
  
 
 
      Posted on Google  
   
   Anatole Kononewsky  
 2. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  The Swanson Reed team have provided our company with exceptional professional advice and assistance for all of our R&D claims for many years - have always achieved great results with excellent value for their services.
  
 
 
      Posted on Google  
   
   Payam Toloo  
 2. June, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Damian Smyth and his team are very helpful, supportive and experts in their field of R&D Tax claims. I'm always happy with the work they do and been a customer of their for over 5 years.
  
 
 
      Posted on Google  
   
   Melissa Doddy  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  The Team at Swanson Reed are very experienced R&D Tax Advisors and gave us ongoing support with all of our R&D Claims, the consultants ensured we were always working with current legislative guidelines, gave us assistance with compiling technical and government documentation and went out their way to ensure they were with us for the entire process from beginning to end.  Highly recommended to anyone who needs assistance with working through what can at times be a daunting process.
  
 
 
      Posted on Google  
   
   Gary Watson  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  We can highly recommend Swanson and Reed as an R & D accountant. We have worked with them for several years now as they make our R & D claim so easy and communicate quickly with both us and our accountant.
  
 
 
      Posted on Google  
   
   Rob van den Bergh  
 31. May, 2022
 
 
 Trustindex verifies that the original source of the review is Google.  Always professional.
  
 
 
  
  Load more

News & Research
News & Research

Draft legislation released for R&D Tax Measures announced in May 2026 Federal Budget

In the Federal Budget handed down on 12 May 2026, The Government proposed major structural changes to the R&D Tax Incentive (RDTI) proposed to commence on 1 July 2028. Proposed reforms announced in May 2026 include: Increasing the offset for […]

DISR Agrifood sector guide for the R&D Tax Incentive

DISR has recently published new specific guidance for the sector. The guidance, titled ‘Agrifood sector guide for the R&D Tax Incentive’ includes worked examples of R&D activity assessment and relevant records claimants should keep. Companies and stakeholders interacting with the […]

AFR Article on how CSL priced the world’s most expensive drug

Post a Comment

Are You Eligible?

R&D Audit Checklist

Quick Contact

Categories

Archives

What Our Clients Say

Quick Contact

News & Research
News & Research

AFR Article on how CSL priced the world’s most expensive drug

Post a Comment

Are You Eligible?

R&D Audit Checklist

Quick Contact

Categories

Archives

What Our Clients Say

Quick Contact

News & Research News & Research

News & Research
News & Research